Takeda has been named in the Dow Jones Sustainabilitz World Index, having more than double the average overall industry score, the company said in a press release Wednesday, noting it was also named in Dow Jones Sustainability Asia Pacific Index for 10th Consecutive Year.
Daiichi Sankyo’s test of HER3 antibody drug conjugate U3-1402 data suggest that targeting HER3 with may be an effective treatment strategy irrespective of mechanism of resistance identified in the setting of EGFR TKI resistance, where new precision treatments are needed, said Helena Yu, MD, Medical Oncologist, Memorial Sloan Kettering Cancer Center, and a trial investigator.
Clover Biopharmaceuticals Doses First Patient in Phase I Study of SCB-313 in China for Peritoneal Carcinomatosis
BEIJING–(BUSINESS WIRE)–Clover Biopharmaceuticals, a biotechnology company focused on developing novel and transformative biologic therapies, today announced that the first patient
Inauguration Ceremony Highlights World-Class, Comprehensive Drug Development Capabilities and More Than Two Decades of Growth in China BURLINGTON, N.C.–(BUSINESS WIRE)–LabCorp®
MicuRx Pharmaceuticals Reports Positive Top-Line Results From a US Phase 2 ABSSSI Clinical Trial of Novel Antibiotic Contezolid Acefosamil
FOSTER CITY, Calif. & SHANGHAI–(BUSINESS WIRE)–MicuRx Pharmaceuticals, Inc., today announced positive top-line results for study MRX4-201, a US Phase 2
Trovagene will present new clinical data from its Phase 2 trial of onvansertib, in combination with Zytiga (abiraterone acetate)/prednisone, in
DelMar Pharmaceuticals said Tuesday that 17 of the first 20 enrolled patients have received at least their first assessment, and nine have been assessed as having achieved a complete response (CR) (9/17, or 53%), seven have been assessed with stable disease (SD), (7/17, or 41%), while nine has been assessed as disease progression (PD) (1/17, or 6%).
Inovio Pharmaceuticals published its positive results from the first-in-human trial of its vaccine against the Middle East Respiratory Syndrome Coronavirus
HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)–Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together
Akebia Therapeutics submitts Vadadustat New Drug Application in Japan for Anemia Due to Chronic Kidney Disease by Collaboration Partner, MTPC
JNDA Submission Represents First Regulatory Submission for Marketing Approval of Vadadustat CAMBRIDGE, Mass.–(BUSINESS WIRE)–Akebia Therapeutics, Inc. (Nasdaq: AKBA), today announced